ZLAB - Zai Lab inks license deal with MediLink for potential cancer drug
2023-04-27 09:17:33 ET
- Zai Lab ( NASDAQ: ZLAB ) signed a licensing agreement with MediLink Therapeutics for a next generation anti-body-drug conjugate (ADC) to treat cancer cancer.
- Zai said via the collaboration, it has expanded its lung cancer franchise and global oncology pipeline with YL212, a novel DLL3 ADC program.
- Under the agreement, MediLink will be eligible to get upfront fees and development and sales-based milestone payments, plus royalties.
- Zai will be responsible for all development and sales activities globally.
- "This collaboration demonstrates our continued focus on developing cancer therapies including ADC drugs, further enriching our global oncology pipeline. It also complements our existing strong lung cancer portfolio," said Rafael Amado, president, head of Global Oncology Research and Development, Zai.
For further details see:
Zai Lab inks license deal with MediLink for potential cancer drug